| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e10a1051ff252b6404cf1d17e16a34da |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2022-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f47a69884865cf08b6354be9154f5b58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f969edb230d1e213fd505267ad6d34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42cf9feba27de82e3b14b4ccd0f56d15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eae1303c6ced3efcf819c4dfcb3589c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b9147d0e0a1e3bde7f84a9e51e2bed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33e67520953575a9b1ec94b5783346b9 |
| publicationDate |
2022-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220167773-A |
| titleOfInvention |
Fc Variants with Modulated Effector Functions and Prolonged Serum Half-Lives |
| abstract |
The present invention relates to a polypeptide comprising an Fc variant in which a portion of the amino acid sequence of an antibody Fc domain is substituted with another amino acid sequence, or an antibody comprising the same. The Fc variants of the present invention may find use in a wide range of antibody and Fc fusion products. In one aspect, the antibodies or Fc fusions of the present invention can be used as therapeutic, diagnostic, or research reagents, preferably therapeutic drugs. The Fc variants of the present invention may exhibit reduced or silenced effector functions while maximizing half-life in the body through optimization of some amino acid sequences. |
| priorityDate |
2021-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |